{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:40:49Z","timestamp":1792802449786,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"DOI":"10.1182\/bloodadvances.2021006555","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T21:09:07Z","timestamp":1645045747000},"page":"5262-5266","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["A phase 1 trial of copanlisib plus ibrutinib in relapsed\/refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"given":"David","family":"Qualls","sequence":"first","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiu Ying","family":"Lam","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4683-1868","authenticated-orcid":false,"given":"Karissa","family":"Whiting","sequence":"additional","affiliation":[{"name":"2Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Owens","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Nichols","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Espeleta","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Qiu","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarima","family":"Subzwari","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Biggar","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Seshan","sequence":"additional","affiliation":[{"name":"2Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie","family":"Batlevi","sequence":"additional","affiliation":[{"name":"1Lymphoma Service, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"38","key":"2022091615285177900_B1","doi-asserted-by":"crossref","first-page":"25332","DOI":"10.18632\/oncotarget.25011","article-title":"The B cell receptor signaling pathway in mantle cell lymphoma","volume":"9","author":"Merolle","year":"2018","journal-title":"Oncotarget."},{"issue":"8","key":"2022091615285177900_B2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia."},{"issue":"6","key":"2022091615285177900_B3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med."},{"key":"2022091615285177900_B4","author":"Swerdlow","year":"2001"},{"issue":"3","key":"2022091615285177900_B5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","article-title":"Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study","volume":"35","author":"Visco","year":"2021","journal-title":"Leukemia."},{"issue":"9","key":"2022091615285177900_B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"issue":"6","key":"2022091615285177900_B7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol."},{"issue":"6","key":"2022091615285177900_B8","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"issue":"12","key":"2022091615285177900_B9","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood."},{"issue":"18","key":"2022091615285177900_B10","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3\u2032-kinase catalytic subunit \u03b1 gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2022091615285177900_B11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell."},{"issue":"1","key":"2022091615285177900_B12","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"2022091615285177900_B13","author":"Davids","year":"2020"},{"issue":"7","key":"2022091615285177900_B14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-020-01108-x","article-title":"Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma","volume":"35","author":"Morschhauser","year":"2021","journal-title":"Leukemia."},{"key":"2022091615285177900_B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2437_38","article-title":"Phase I\/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed\/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma","volume":"35","author":"Batlevi","year":"2017","journal-title":"Hematol Oncol."},{"issue":"1","key":"2022091615285177900_B16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-21-2183","article-title":"Phase I\/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring","volume":"28","author":"Stewart","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2022091615285177900_B17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol."},{"issue":"7","key":"2022091615285177900_B18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol."},{"key":"2022091615285177900_B19","year":"2020"},{"issue":"1","key":"2022091615285177900_B20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol."},{"issue":"4","key":"2022091615285177900_B21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clml.2020.09.007","article-title":"Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5262\/1920162\/advancesadv2021006555.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5262\/1920162\/advancesadv2021006555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T15:29:20Z","timestamp":1663342160000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/18\/5262\/484068\/A-phase-1-trial-of-copanlisib-plus-ibrutinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006555","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}